Zhenbin Ding, Hong Wu, Yongyi Zeng, Ming Kuang, Wei Yang, Zhiqiang Meng, Yajin Chen, Chunyi Hao, Shubing Zou, Huichuan Sun, Chang Liu, Kecan Lin, Guoming Shi, Xiaoying Wang, Xiutao Fu, Rongxin Chen, Yi Chen, Ruifang Liang, Takeshi Kano, Huiyan Pan, Suna Yang, Jia Fan, Jian Zhou
PURPOSE: Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 109 /L) patients undergoing elective invasive procedures. METHODS: In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 109 /L that increased to ≥ 20 × 109 /L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed...
October 18, 2022: Hepatology International